Biogen Stock News

Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody for B-cell non-Hodgkin's lymphoma (

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogen''s Board of Directors, effective at the tim…

Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.

These stocks aren't safe, but they have the potential to generate some great returns in the long run.

Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics

Biogen Inc. ( BIIB , Financial) announced on Thursday that it has entered into an agreement that will see Samsung BioLogics ( XKRX:207940 , Financial) acquire Biogen's equity stake in the Samsung Bioe

Biogen will be selling its stake in a biosimilars joint venture to partner Samsung Biologics for up to $2.3 billion.

Biogen (BIIB) announced an agreement with Samsung Biologics whereby the company will sell its stake in the Samsung Bioepis joint venture to the South Korean partner, Samsung BioLogics,

Biogen (BIIB) and Eisai (ESALF) announce additional details about the Phase 4 confirmatory study, ENVISION, of Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use in

LABU - A Compelling Biotech Trade

The company is still dealing with the fallout of a controversial regulatory approval.

The Centers for Medicare and Medicaid may ensure the commercial death of Biogens controversial Alzheimers drug. And that leads at least one analyst to wonder if more radical steps need to be taken.

The Centers for Medicare and Medicaid may ensure the commercial death of Biogen's controversial Alzheimer's drug. And that leads at least one analyst to wonder if more radical steps need to be taken.

Groups supporting Alzheimer patients are putting pressure on the Centers for Medicare and Medicaid Services to reverse a preliminary decision that severely limits coverage

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.